Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...

Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than ...

In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory mutant NPM1 acute ...

Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...

When resistance to or failure of hypomethylating agents (HMAs) occurs in acute myeloid leukemia (AML), depleting a ligase ...

A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...

(RTTNews) - Syndax Pharmaceuticals, Inc. (SNDX), Tuesday announced positive results from the relapsed or refractory mutant NPM1 acute myeloid leukemia cohort in the pivotal Phase 2 portion of the ...

A new study reveals a modular CAR-T approach that effectively targets heterogeneous antigens in paediatric acute myeloid leukaemia, enhancing treatment success through combinatorial targeting.

THRAP3, STMN1, and GNA13—are overrepresented in blood cancers like acute myeloid leukemia (AML) and could prove to be novel ...

Unless expressly exempted, AML programs must be applied to all advisory activities. Covered advisers must apply AML programs to all advisory activities, with only a handful of activity- and ...

The trial aims to assess Luvelta's efficacy and safety, with most of its sites due to open by the end of the year.